Achieve Life Sciences, Inc.
ACHVHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Achieve Life Sciences, Inc. focuses on Biotechnology services and products. Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. Valued at $806.8M, ACHV is a small-cap name in its sector. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Market Cap
$806.8M
Beta
2.25
P/E (TTM)
—
P/E (Fwd)
-12.32
EPS (TTM)
$-1.66
EPS (Fwd)
$-0.64
ROE
-845.0%
ROA
-29.2%
Cash
$187.3M
Total Debt
$14.9M
Free CF
$156.3M
52W Change
158.8%
Annual Financials
Cash vs Debt
Where ACHV stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ACHV finished 59.27% above its 150-day moving average ($5.18) and 62.08% above its 200-day moving average ($5.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACHV overbought or oversold?
At the September 2, 2026 close, ACHV's RSI(14) was 71.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $187.3M in cash and $14.9M in debt, ACHV maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $156.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -845.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, ACHV tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, ACHV has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Achieve Life Sciences, Inc. and its sector.